Keros Therapeutics Inc

NASDAQ:KROS  
36.82
+0.69 (+1.91%)
Earnings Announcements

Keros Therapeutics Reports First Quarter 2022 Financial Results

Published: 05/05/2022 12:48 GMT
Keros Therapeutics Inc (KROS) - Keros Therapeutics Reports First Quarter 2022 Financial Results.
Keros Therapeutics Inc - Expects Cash It Had on Hand at March 31, 2022 Will Fund Operating Expenses and Capital Expenditure Requirements Into Q1 of 2024.
Keros Therapeutics Inc - Qtrly Loss per Share $1.01.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$1.07

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$1.14

More details on our Analysts Page.